Divi's Laboratories Share Price Target 2026, 2027, 2028, 2029, 2030

Divi’s Laboratories share price today

Divi’s Laboratories Ltd (NSE: DIVISLAB) is an API and pharmaceutical CDMO business with a market capitalisation of ₹2,22,675 Cr in Gale’s internal 6 August 2026 research snapshot. The stock was recorded at ₹8,275, against a 52-week range of ₹5,690 to ₹8,585. The live box above updates independently; every fundamental ratio below stays tied to the dated snapshot so market movement is never confused with a refreshed financial statement.

The central case is CDMO quality, recovery optionality and an unforgiving valuation. A high-purity API and custom-synthesis franchise with 35% operating margins, zero debt and long innovator relationships. The internal figures show 22.0% ROCE, 16.5% ROE and 5.7% five-year profit growth. Those are attractive headline numbers, but the stock market pays for what comes next. This article therefore separates business quality, current momentum and valuation instead of treating them as one idea.

What the business actually earns money from

Divi’s manufactures active pharmaceutical ingredients and performs custom synthesis for global innovator customers. Regulatory capability, process chemistry, scale and a history of reliable delivery matter more than consumer branding. Long relationships can create sticky revenue, but individual products and customer programmes can still make growth lumpy.

The durable advantage is process chemistry, regulatory execution and long innovator relationships at global scale. A moat should show up in numbers, not adjectives. Here the tests are return on capital, margin resilience, market-share behaviour and the amount of balance-sheet funding needed to grow. The snapshot’s 22.7% five-year average ROCE is more informative than a single strong year because it spans changes in demand and input costs.

Regulatory capability and customer trust reduce switching, but they do not make a CDMO pipeline predictable. Innovator programmes can be delayed, generic API prices can fall and customer inventory corrections can interrupt orders. Divi’s balance sheet can absorb volatility; its premium valuation may not if several high-expectation projects move right at the same time.

The investment debate

The 35.3% operating margin and debt-free balance sheet demonstrate franchise quality. The weak point is the price paid for that quality: trailing profit growth is modest against a roughly 75-times multiple. Recovery in custom-synthesis projects and new capacity can lift earnings, but a forecast should not treat every pipeline molecule as commercial revenue before it arrives.

The historical growth split helps frame that debate. Sales compounded at 8.7% and profit at 5.7% over five years. Over three years those rates were 10.8% and 12.9%. Profit growth has accelerated versus the five-year record. That is not automatically bullish or bearish: acceleration can reflect a sustainable mix shift or a low base, while deceleration can be temporary or the first evidence that the old multiple is no longer deserved.

The stock sat about 3.6% below its 52-week high and 45.4% above its low in the snapshot. Distance from a high is not valuation. It is useful only when paired with earnings, balance-sheet and competitive evidence.

Generic APIs and custom synthesis should not be valued alike

Divi’s has two distinct economic engines. Generic APIs can benefit from process efficiency, regulatory approvals and global scale, but product pricing is exposed to competition and customer inventory cycles. Custom synthesis work is tied to innovator programmes, where chemistry capability, confidentiality and reliable execution can create deeper relationships. The latter can be stickier, yet programme timing and molecule success make revenue uneven.

The mix matters more than a single quarterly sales number. Growth led by a favourable custom-synthesis project may carry a different margin and duration from a volume recovery in generic APIs. Investors should look for repeat orders, commercialisation milestones and asset utilisation rather than annualising one launch. The base case assumes a balanced recovery; the bull case needs a broader project ramp, while the bear case recognises that customer pipelines can slip without warning.

Why a 35% margin deserves scrutiny, not automatic extrapolation

The 35.3% operating margin in Gale’s snapshot demonstrates unusually strong pharmaceutical manufacturing economics. It reflects process yields, backward integration, product mix and high utilisation, not a permanent contractual entitlement. Raw-material changes, pricing pressure, plant maintenance or an unfavourable project mix can compress it. A model that applies today’s margin to every future rupee of revenue would hide that operating risk.

The more durable evidence is Divi’s ability to defend margins across product cycles while maintaining regulatory compliance. Investors should compare gross-margin movement with custom-synthesis mix, inventory and capacity utilisation. Sustained sales growth with stable cash margin would support the quality premium. Revenue growth bought through lower pricing, or margin gains caused solely by temporary input relief, deserves a more conservative multiple.

Capacity has value only when customers qualify it

Pharmaceutical plants cannot be treated like generic industrial sheds. New capacity needs validation, regulatory readiness and customer qualification before it earns at scale. Cash leaves during construction, but commercial revenue can arrive much later. Divi’s debt-free position reduces financing risk; it does not eliminate execution or opportunity cost.

That lag is central to the valuation. A capital programme can suppress free cash flow before improving EPS, and delayed customer approvals can extend the gap. Monitor capital work in progress, asset turns, depreciation, inventory and operating cash flow together. If utilisation and ROCE recover as capacity fills, the investment creates an additional earnings runway. If assets remain underused while the market prices a rapid ramp, multiple compression can offset otherwise respectable business growth.

Growth, margins and capital efficiency

Operating evidence	6 Aug 2026 snapshot	How to read it
Sales CAGR, 5 years	8.7%	Demand, pricing and consolidation together
Profit CAGR, 5 years	5.7%	Includes margin and financial leverage
Sales CAGR, 3 years	10.8%	More recent top-line momentum
Profit CAGR, 3 years	12.9%	More recent earnings momentum
Operating margin	35.3%	Business-model economics before interest and tax
ROCE / five-year ROCE	22.0% / 22.7%	Current return versus durability
ROE	16.5%	Return delivered on shareholder equity

Divi’s 35.3% operating margin is the result of product mix, chemistry yields and regulatory execution, not merely high prices. ROCE tests whether that margin is earned efficiently on plants and working capital. The best evidence would be new capacity filling while both measures remain strong. A high accounting margin paired with falling asset turns and ROCE would show that the next growth leg is taking longer to monetise.

Recent profit growth has improved from the five-year record, but neither period supports an automatic continuation of a 75-times multiple. Project timing can make any short window misleading. Gale’s base assumption sits between a stalled pipeline and a full utilisation boom, with valuation compression doing part of the work even if operating performance improves.

Balance sheet, ownership and cash-flow questions

Debt to equity of 0.00 is negligible, so operating performance rather than refinancing risk should drive the case. Promoter holding is 51.88%. The snapshot records zero promoter pledge, removing one common governance risk, though it does not replace scrutiny of related-party transactions and capital allocation.

Balance-sheet and ownership check	Snapshot
Debt to equity	0.00
Promoter holding	51.88%
Promoter pledge	0.00%
Book value per share	₹631.15
Dividend yield	0.36%

Divi’s cash conversion should be read through inventory built for customer campaigns, receivables, tax and the large cash outlay on qualified capacity. A debt-free balance sheet allows patience, yet shareholders still need evidence that capital work in progress becomes productive assets. Several years of rising depreciation without matching operating cash would weaken the recovery case.

Dividend yield of 0.36% is not the main reason to own the stock; most of the expected return must come from earnings growth and valuation discipline. The payout should be viewed after necessary reinvestment, not in isolation.

The numbers

Metric	Internal research snapshot
Market capitalisation	₹2,22,675 Cr
Snapshot price	₹8,275
P/E · price/book	74.7 · 13.29
PEG · EV/EBITDA	13.09 · 49.6
ROE · ROCE	16.5% · 22.0%
Operating margin	35.3%
Debt/equity	0.00
EPS (TTM)	₹112.23
Book value per share	₹631.15
52-week range	₹5,690 – ₹8,585

Valuation: what today’s multiple already assumes

The snapshot P/E is 74.7 times, price/book 13.29 times, PEG 13.09, and EV/EBITDA 49.6 times. No one ratio settles the case. P/E connects price to shareholder earnings; EV/EBITDA helps compare operations before financing; price/book matters when the asset base is economically meaningful; PEG is only as reliable as the growth rate placed beneath it.

Quality alone is not a buying signal. At the recorded valuation, execution must justify a substantial premium; a wider margin of safety matters more than a confident story. The target framework compounds the recorded TTM EPS of ₹112.23 and applies different exit multiples. It does not assume that today’s multiple survives automatically. That distinction matters because a company can grow profit while its share price disappoints if the starting valuation was too optimistic.

Scenario	EPS growth assumption	Exit P/E	What must be true
Bear	6%	43×	Competitive or cyclical pressure slows growth and the premium contracts
Base	11%	58×	The core franchise executes without assuming a perfect cycle
Bull	17%	73×	Growth stays strong and the market continues to pay for quality

Divi’s Laboratories share price target 2026 to 2030

The bear, base and bull paths use the assumptions above for every year through 2030. They are scenario arithmetic, not a forecast of where the share must trade. The model uses one consistent diluted EPS base and rounds only the displayed outcomes. Dividends are not added to the price targets, so total shareholder return would differ from the table.

Scenario warning: earnings, capital structure and market multiples can all move outside these assumptions. Read the range as a sensitivity map, never as a promise or personalised recommendation.

The table is intentionally gated to a free signed-in account. That keeps the assumptions and target grid together, prevents a single number from being lifted out of context, and lets Gale show the member-only accumulation range separately from the public research.

What would change our mind

The thesis should be reviewed against measurable evidence, not daily price movement:

• Custom-synthesis project additions and customer concentration. A sustained adverse trend matters more than one noisy quarter.
• API pricing, volume and product mix. A sustained adverse trend matters more than one noisy quarter.
• Regulatory observations and remediation. A sustained adverse trend matters more than one noisy quarter.
• Capacity utilisation and cash return on new plants. A sustained adverse trend matters more than one noisy quarter.

We would also revisit the model if equity dilution, a large acquisition or a material accounting change altered EPS comparability. Targets are not “set and forget”; the framework must be rebuilt when the business base changes.

Should you buy at the current price?

Divi’s Laboratories is a business to admire without automatically chasing the share. At this valuation, patience is an active decision: wait for either earnings to catch up or price to create a genuine margin of safety.

The signed-in panel shows Gale’s current rating, while paid members can see the accumulation range. Neither replaces position sizing or personal suitability. An investor already heavily exposed to pharma cdmo faces a different decision from someone building a diversified portfolio.

FAQ

What is the Divi’s Laboratories share price target for 2030?

Gale publishes bear, base and bull outcomes for 2026–2030 in the signed-in table on this page. Each number comes from the stated EPS growth and exit P/E assumptions; there is no single assured target.

Is Divi’s Laboratories overvalued?

At 74.7 times earnings and 49.6 times EV/EBITDA in the snapshot, the shares require strong and durable execution. Valuation becomes attractive only when the return implied by conservative assumptions compensates for the business risks.

What is Divi’s Laboratories’ main advantage?

The core advantage is process chemistry, regulatory execution and long innovator relationships at global scale. The evidence to follow is whether that advantage continues to produce stable market share, margins and returns on capital.

What is the biggest risk to the target model?

Customer/product concentration, regulatory execution and a 75-times earnings multiple make delays costly. A lower growth rate and a lower multiple can occur together, which is why the bear path changes both variables.

Does Divi’s Laboratories pay a dividend?

The internal snapshot records a 0.36% dividend yield. It is secondary to earnings growth, and future payouts remain subject to board decisions and cash needs.

When are Divi’s Laboratories’ next results?

Use Gale’s results calendar for the announced date and check the exchange filing before relying on an estimate.

Related research

• Sun Pharma share price target
• Zydus Lifesciences share price target
• Glenmark Pharma share price target

Sources: Screener.in company financials, captured in Gale’s approved internal research snapshot on 6 August 2026; company results, annual reports and exchange filings linked from that page. Live market price is supplied separately by Yahoo Finance and is indicative.

---

This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.